Takeda Pharma To Explore Plasma Derived-therapy For COVID-19 - Quick Facts

(RTTNews) - Takeda Pharmaceutical Company Limited (TAK), a global biopharmaceutical company headquartered in Japan, said it is initiating the development of a potential anti-SARS-CoV-2 polyclonal H-IG, which Takeda is referring to as TAK-888. SARS-CoV-2 is the virus that causes COVID-19. The company is currently in talks with multiple national health and regulatory agencies and health care partners in the US, Asia, and Europe to expeditiously move the research into TAK-888 forward.

Also, Takeda is exploring whether select marketed therapies and molecules in its drug library could be viable candidates for the effective treatment of COVID-19.

Separately, Takeda Pharma announced the completion of its previously-announced sale of a portfolio of select products to STADA for a total value of $660 million. Approximately 450 employees have transitioned, as part of the deal.